Exhibit 99.2
BEAMR IMAGING LTD.
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS OF JUNE 30, 2024
BEAMR IMAGING LTD.
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS OF JUNE 30, 2024
INDEX TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
F-1
BEAMR IMAGING LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands except share and per share amounts)
| As of June 30, |
As of December 31, |
|||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Short-term bank deposit | ||||||||
| Trade receivables | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Property and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Total non-current assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current maturities of loans, net | $ | $ | ||||||
| Account payables | ||||||||
| Deferred revenues | ||||||||
| Liability to controlling shareholder, net | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Non-current liabilities: | ||||||||
| Loans, net of current maturities | ||||||||
| Derivative warrant liability | ||||||||
| Total non-current liabilities | ||||||||
| Commitments and contingent liabilities | ||||||||
| Shareholders’ equity: | ||||||||
| Ordinary Shares of NIS |
||||||||
| Authorized: |
||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( |
) | ( |
) | ||||
| Total shareholders’ equity | ||||||||
| Total liabilities and shareholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-2
BEAMR IMAGING LTD.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(U.S. dollars in thousands except share and per share amounts)
| Six-month period ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Revenues | $ | $ | ||||||
| Cost of revenues | ( |
) | ( |
) | ||||
| Gross profit | ||||||||
| Research and development expenses | ( |
) | ( |
) | ||||
| Sales and marketing expenses | ( |
) | ( |
) | ||||
| General and administrative expenses | ( |
) | ( |
) | ||||
| Operating loss | ( |
) | ( |
) | ||||
| Financing income (expense), net | ( |
) | ||||||
| Loss before taxes on income | ( |
) | ( |
) | ||||
| Taxes on income | ( |
) | ( |
) | ||||
| Net loss and comprehensive loss for the period | $ | ( |
) | $ | ( |
) | ||
| Basic net loss per share | $ | ( |
) | $ | ( |
) | ||
| Weighted average number of Ordinary Shares outstanding used in computing basic net loss per share | ||||||||
| Diluted net loss per share | $ | ( |
) | $ | ( |
) | ||
| Weighted average number of Ordinary Shares outstanding used in computing diluted net loss per share | ||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-3
BEAMR IMAGING LTD.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
(U.S. dollars in thousands except share and per share amounts)
| Ordinary shares | Convertible Ordinary 1 and 2 shares | Convertible Preferred shares | Additional paid-in | Accumulated | Total shareholders’ Equity | |||||||||||||||||||||||||||||||
| Number | Amount | Number | Amount | Number | Amount | capital | deficit | (deficit) | ||||||||||||||||||||||||||||
| Balance as of December 31, 2022 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Issuance of Ordinary Shares upon completion of an initial public offering, net of offering expenses | - | - | ||||||||||||||||||||||||||||||||||
| Voluntary conversion of all shares with preferences over Ordinary Shares into Ordinary Shares | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Automatic conversion of all convertible advanced investments into Ordinary Shares | - | - | ||||||||||||||||||||||||||||||||||
| Deemed dividend resulted from trigger of down round protection feature of certain warrants granted | - | - | - | ( | ) | |||||||||||||||||||||||||||||||
| Share-based compensation (Note 4) | - | - | - | |||||||||||||||||||||||||||||||||
| Exercise of options into ordinary shares to be issued (Note 4) | - | - | ||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance as of June 30, 2023 (unaudited) | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| (*) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-4
BEAMR IMAGING LTD.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
(U.S. dollars in thousands except share and per share amounts)
| Ordinary shares | Additional paid-in | Accumulated | Total shareholders’ | |||||||||||||||||
| Number | Amount | capital | Deficit | Equity | ||||||||||||||||
| Balance as of December 31, 2023 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Issuance of Ordinary Shares upon completion of an initial public offering (including exercise of over-allotment option), net of offering expenses (Note 3A) | ||||||||||||||||||||
| Issuance of Ordinary Shares upon cashless exercise of Warrants (Note 3B) | ( | ) | ||||||||||||||||||
| Amount classified to equity upon determination of the exercise price (Note 3B) | ||||||||||||||||||||
| Share-based compensation (Note 4) | - | |||||||||||||||||||
| Exercise of options into ordinary shares to be issued (Note 4) | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balance as of June 30, 2024 (unaudited) | $ | $ | $ | ( | ) | $ | ||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-5
BEAMR IMAGING LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)
| Six-month period ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Share-based compensation (Note 4) | ||||||||
| Change in the fair value of convertible advanced investments | ( | ) | ||||||
| Amortization of discount on straight loan received from commercial bank | ||||||||
| Exchange rate differences on straight loan received from commercial bank | ( | ) | ( | ) | ||||
| Change in the fair value of derivative warrant liability (Note 5) | ( | ) | ||||||
| Change in estimation of maturity date of liability to controlling shareholder (Note 6) | ||||||||
| Amortization of discount and accrued interest on straight loan from controlling shareholder (Note 6) | ||||||||
| Exchange rate differences on straight loan from controlling shareholder (Note 6) | ( | ) | ( | ) | ||||
| Decrease (increase) in trade receivables | ||||||||
| Increase in other current assets | ( | ) | ( | ) | ||||
| Decrease in accounts payable | ( | ) | ( | ) | ||||
| Decrease in deferred revenues | ( | ) | ( | ) | ||||
| Increase in other current liabilities | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ||||
| Capitalization of internal-use software | ( | ) | ||||||
| Investment is short-term bank deposit | ( | ) | ||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Repayment of principal relating to straight loan received from commercial bank | ( | ) | ( | ) | ||||
| Net proceeds received upon completion of initial public offering transaction | ||||||||
| Net proceeds received upon completion of public offering transaction (Note 3A) | ||||||||
| Proceeds from loan received from controlling shareholder (Note 6) | ||||||||
| Repayment of principal relating to straight loan received from controlling shareholder (Note 6) | ( | ) | ( | ) | ||||
| Proceeds received from exercise of options into shares to be issued (Note 4) | ||||||||
| Net cash provided by financing activities | ||||||||
| Change in cash, cash equivalents | ||||||||
| Cash, cash equivalents at beginning of period | ||||||||
| Cash, cash equivalents at end of period | $ | $ | ||||||
| Non-cash financing activities: | ||||||||
| Amount classified to equity upon determination of the exercise price (Note 3) | $ | $ | ||||||
| Share-based compensation capitalized in internal-use software | $ | $ | ||||||
| Automatic conversion of convertible advanced investments into shares | $ | $ | ||||||
| Deemed dividend upon trigger of down round protection | $ | $ | ( | ) | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Interest paid | $ | $ | ||||||
| Interest received | $ | $ | ||||||
| Taxes paid | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
F-6
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars in thousands)
NOTE 1 - GENERAL
| A. | Operations |
Beamr Imaging Ltd. (the “Company” or “Beamr”) was incorporated on October 1, 2009 under the laws of the State of Israel and it engages mainly development of optimization technologies for video and photo compression.
On February 20, 2024, the Company launched its next generation product, a cloud-based software-as-a-Service (“SaaS”) solution that aims to simplify video processing and make it accessible and affordable to everyone. On June 11, 2024, the Company announced that its SaaS solution is available on Oracle Cloud Infrastructure cloud.
| B. | Foreign operations |
| 1. | Beamr Inc. |
In 2012, the Company incorporated a wholly-owned U.S. subsidiary, Beamr Inc. (“Beamr Inc.”), for the purpose of reselling the Company’s software and products in the U.S. market.
| 2. | Beamr Imaging RU LLC |
In 2016, the Company incorporated a wholly-owned limited Russian partnership, Beamr Imaging RU LLC (“Beamr Imaging RU”), for the purpose of conducting research and development services to the Company.
The Company and its subsidiaries, Beamr Inc. and Beamr Imaging RU, are collectively referred to as the “Group”.
| C. | Liquidity and capital resources |
The Company has devoted substantially
all of its efforts to research and development, the commercialization of its software and products and raising capital for such purposes.
The development and further commercialization of the Company’s software and products are expected to require substantial further expenditures.
To date, the Company has not yet generated sufficient revenues from operations to support its activities, and therefore it is dependent
upon external sources for financing its operations. During the six month period ended June 30, 2024, the Company had net losses of $
During the year ended December 31,
2023, the Company raised net proceeds of $
In addition, on
March 8, 2024, the Company’s filed a shelf registration statement on Form F-3 (the “Shelf Registration Statement”), which
was declared effective by the Securities and Exchange Commission (the “SEC”) on March 19, 2024, which permits the Company
to register up to $
Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that it has sufficient cash to fund its planned operations for at least the next 12 months.
F-7
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 1 - GENERAL (Cont.)
| D. | The impact of the Russian Invasion of Ukraine |
On February 24, 2022, Russia invaded Ukraine. The Company has an operation in Russia through its wholly-owned subsidiary, Beamr Imaging RU. The Company undertakes some of its software development and design, quality assurance and support in Russia using personnel located there. While most of the Company’s developers are located in Russia, its research and development leadership are all located in Israel. The Company has no manufacturing operations in Russia, and the Company does not sell any products in Russia. The Company constantly evaluates its activities in Russia and currently believes there was no significant impact on its activities. As of June 30, 2024, two employees have relocated from Russia to Serbia and are employes as subcontractors of the Company.
| E. | The impact of Iron Sword War (Israel-Hamas war) |
On October 7, 2023, the State of Israel was attacked by the Hamas terrorist organization, and as a result, the State of Israel declared a state of war and a large-scale mobilization of reserves (the “War”) which is an exceptional event with security and economic implications, the scope and outcome of which cannot be predicted. Following the outbreak of the War, the State of Israel took and is continuing to take significant steps to maintain the security of Israeli residents, which has had and continues to have a significant impact on economic and business activity in the country. The management regularly monitors developments and acts in accordance with the guidelines of the various authorities. Since this is an event beyond the Company’s control and characterized by uncertainty, inter alia as to when the War will end, as of the approval date of these unaudited condensed interim consolidated financial statements, the Company is unable to predict the intensity of the impact of the War on the Company’s financial condition and the results of its operations.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
| A. | Basis of presentation |
The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the SEC on March 4, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
The results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period.
| B. | Use of estimates in the preparation of financial statements |
The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include (i) revenues recognition; (ii) recoverability of the Company’s goodwill upon subsequent periods and (iii) measurement of fair value of equity awards.
| C. | Principles of Consolidation |
The consolidated financial statements include the accounts of the Group. Intercompany transactions and balances have been eliminated upon consolidation.
| D. | Cash and cash equivalents |
Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.
F-8
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (Cont.)
| E. | Short-term bank deposit |
Short-term bank deposit in banking institution for a period in excess of three months but less than one year following the date of deposit. The deposit is presented in accordance with the deposit terms.
| F. | Basic and diluted net loss per ordinary share |
Until the completion
of the IPO in March 2023, the Company applied the two-class method as required by ASC 260-10, “Earnings Per Share” (“ASC 260-10”),
which requires the income or loss per share for each class of shares (ordinary and all other shares with preferences over ordinary shares)
to be calculated assuming
Basic net loss per ordinary share is computed by dividing the net loss for the period applicable to ordinary shareholders, by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants and using the if-converted method with respect to convertible advanced investments and certain stock warrants accounted for as derivative financial liability. In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.
During the six month
periods ended June 30, 2024 and 2023, the total weighted average number of Ordinary Shares related to then outstanding shares with preferences
over Ordinary Shares (Convertible Ordinary 1 and 2 shares and Convertible Preferred Shares), share options and share warrants that were
excluded from the calculation of the diluted loss per share was
| Six-month period ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Numerator: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Deemed dividend related to trigger of down round protection feature resulting from completion of an IPO | ( | ) | ||||||
| Net basic loss | $ | ( | ) | $ | ( | ) | ||
| Change in fair value of derivative warrant liability | ( | ) | ||||||
| Change in fair value of convertible advanced investment | ( | ) | ||||||
| Net diluted loss | $ | ( | ) | $ | ( | ) | ||
| Denominator: | ||||||||
| Ordinary shares used in computing basic net loss per share | ||||||||
| Incremental ordinary shares to be issued upon exercise of derivative warrant liability | ||||||||
| Incremental ordinary shares to be issued upon conversion of convertible advanced investments | ||||||||
| Ordinary shares used in computing diluted net loss per share | ||||||||
| Basic net loss per ordinary share | $ | ( | ) | $ | ( | ) | ||
| Diluted net loss per ordinary share | $ | ( | ) | $ | ( | ) | ||
F-9
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 3 - SIGNIFICANT TRANSACTIONS
| A. | Completion of underwritten U.S. public offering |
On February 12, 2024, the Company
announced the pricing of an underwritten U.S. public offering under which
On February 13, 2024, the over-allotment
option was fully exercised by the underwriter for additional gross proceeds of approximately $
Direct and incremental costs incurred
related to the IPO amounted to $
Upon satisfaction of customary closing conditions, the offering closed on February 15, 2024.
| B. | Partial cashless exercise of warrants |
| 1. | During the six month period ended June 30, 2024, the Company
issued |
| 2. | On February 22, 2024, a written notice was received by the
Company from IBI under which the exercise price of the warrant share granted in previous period to IBI to purchase |
In addition, during the six month
period ended June 30, 2024, the Company issued
F-10
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 4 - SHARE OPTIONS
On January 11, 2015, the Company’s Board of Directors approved and adopted the 2015 Share Incentive Plan (the “Plan”), pursuant to which the Company’s Board of Directors may award share options to purchase the Company’s Ordinary Shares as well as restricted shares, RSUs and other share-based awards to designated participants. Subject to the terms and conditions of the Plan, the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designated participants; (ii) the terms and provisions of the respective award agreements, including, but not limited to, the number of options to be granted to each optionee, the number of shares to be covered by each option, provisions concerning the time and the extent to which the options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the fair market value of the shares covered by each award; (iv) make an election as to the type of approved 102 Option under Israeli tax law; (v) designate the type of award; (vi) take any measures, and take actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vii) interpret the provisions of the Plan and to amend from time to time the terms of the Plan.
On May 22, 2024, the Company’s Board of Directors
approved to increase the number of Ordinary Shares, reserved out of the Company’s registered share capital, to be issued under the
Plan by additional
The Plan permits the grant of up to
| Number of Share Options | Weighted Average Exercise Price | Weighted average remaining contractual life | Intrinsic value | |||||||||||||
| $ | (years) | $ | ||||||||||||||
| Outstanding as of December 31, 2023 | ||||||||||||||||
| Granted | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Cancelled | ( | ) | ||||||||||||||
| Outstanding as of June 30, 2024 (unaudited) | ||||||||||||||||
| Exercisable as of June 30, 2024 (unaudited) | ||||||||||||||||
| Number of Share Options | Weighted Average Exercise Price | Weighted average remaining contractual life | Intrinsic value | |||||||||||||
| $ | (years) | $ | ||||||||||||||
| Outstanding as of December 31, 2022 | ||||||||||||||||
| Granted | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Forfeited or expired | ( | ) | ||||||||||||||
| Outstanding as of June 30, 2023 (unaudited) | ||||||||||||||||
| Exercisable as of June 30, 2023 (unaudited) | ||||||||||||||||
The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the estimated fair value of the Company’s ordinary shares on the last day of the second quarter of each of the applicable reporting periods and the exercise price, multiplied by the number of in-the-money share options) that would have been received by the share option holders had all option holders exercised their share options on June 30 of each of the applicable reporting periods. This amount is impacted by the changes in the fair market value of the Company’s ordinary share.
F-11
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 4 - SHARE OPTIONS (Cont.)
| Exercise price | Share options outstanding as of June 30, 2024 | Weighted average remaining contractual term | Share options exercisable as of June 30, 2024 | Weighted average remaining contractual term | ||||||||||||
| Unaudited | ||||||||||||||||
| (years) | (years) | |||||||||||||||
The weighted average grant date fair value of
share options granted during the six month periods ended June 30, 2024 and 2023, was $
| six-month period ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| Volatility (%) | ||||||||
| Risk-free interest rate (%) | ||||||||
| Dividend yield (%) | ||||||||
| Expected life (years) | ||||||||
| Exercise price ($) | ||||||||
| Share price ($) | ||||||||
As of June 30, 2024, there was $
| Six-month period ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Research and development | $ | $ | ||||||
| Sales and marketing | ||||||||
| General and administrative | ||||||||
| $ | $ | |||||||
F-12
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 5 - FINANCING EXPENSES (INCOME), NET
| Six-month period ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Change in fair value of convertible advanced investment | $ | $ | ( |
) | ||||
| Change in fair value of derivative warrant liability | ( |
) | ||||||
| Amortization of discount and accrued interest relating to straight loan received from commercial bank | ||||||||
| Amortization of discount relating to loan received from controlling shareholder | ||||||||
| Change in accounting estimates related to maturity date of loan received from controlling shareholder | ||||||||
| Interest on bank deposits | ( |
) | ( |
) | ||||
| Exchange rate differences and other finance expenses | ( |
) | ( |
) | ||||
| $ | $ | ( |
) | |||||
NOTE 6 - RELATED PARTIES TRANSACTIONS
The liability to controlling shareholder derives
from a service agreement with the Company’s Founder under which the Company receives consulting services on recurring basis from the Founder
as Chief Executive Officer indirectly through an entity controlled by the Founder (the “Service Provider”) for total current
monthly gross amount of NIS
On May 22, 2024, the Company’s Compensation Committee and Board of Directors approved a certain adjustment of the compensation terms and conditions of the Founder for his duties as Chief Executive Officer of the Company, so that the salary of the Founder shall be increased by NIS 20 thousand (the “Founder’s Compensation Adjustment”). However, the Founder’s Compensation Adjustment is subject to reaffirmation of the general meeting of the shareholders which was achieved on August 5, 2024.
On February 16, 2022, the Company entered into
an addendum to the aforesaid service agreement with the Service Provider under which it was agreed that (i) the term of the service agreement
with the Service Provider was extended to December 31, 2025 and (ii) the then current liability towards the Service Provider as was accrued
for services rendered under the service agreement over a period commencing January 1, 2020 through the date hereof in total nominal amount
of $
Since the liability towards the Founder was considered
as free interest loan, which did not represent the applicable rate of risk for the Company, the aforesaid addendum was accounted for as
a capital contribution from a controlling shareholder. Thus, the liability towards the Founder was measured at fair value based on future
cash payments discounted using an interest rate of
As of December 31, 2022, management has updated
the repayments schedule of the obligation based on its current projection of the availability of funds. Accordingly, the obligation was
expected to be repaid over the subsequent 24-month period. However, the Commencement Date was determined to be the pricing date of the
IPO (February 27, 2023) under which the liability in nominal amount of NIS
F-13
BEAMR IMAGING LTD.
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Cont.)
(U.S. dollars in thousands)
NOTE 6 - RELATED PARTIES TRANSACTIONS (Cont.)
| Six-month period ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Opening balance | $ | $ | ||||||
| Accrued liability in respect to additional services rendered | ||||||||
| Repayment of liability to controlling shareholder | ( |
) | ( |
) | ||||
| Change in estimation of maturity date of liability to controlling shareholder | ||||||||
| Amortization of discount relating to liability to controlling shareholder | ||||||||
| Exchange rate differences | ( |
) | ( |
) | ||||
| Closing balance | $ | $ | ||||||
| As of June 30, | As of December 31, | |||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| First year (current maturities) | $ | | $ | |||||
| Second year | ||||||||
| Closing balance | $ | $ | ||||||
| Six-month period ended June 30, |
||||||||
| 2024 | 2023 | |||||||
| Unaudited | ||||||||
| Research and development | $ | $ | ||||||
| Sales and marketing | ||||||||
| General and administrative | ||||||||
| $ | $ | |||||||
The allocation was done based on the management estimation to reflect the contribution to the related activity.
NOTE 7 - SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any other significant subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.
| A. | Grant of options |
On July 23, 2024,
the Company’s Board of Directors approved a grant of options to purchase
F-14